Salvage therapy with177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 51, Issue 3, 2010, Pages 383-390

  Van Essen, Martijn ^a   Krenning, Eric P ^a   Kam, Boen L R ^a   De Herder, Wouter W ^a   Feelders, Richard A ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

177Lu octreotate; Additional therapy; Carcinoid; Neuroendocrine tumors; Salvage therapy

Indexed keywords

OCTREOTATE LU 177; TRACER; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; CHROMOGRANIN A; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ARTICLE; BONE MARROW TOXICITY; BRONCHUS TUMOR; CLINICAL ARTICLE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; ADULT; AGED; BLOOD; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BRONCHIAL NEOPLASMS; CHROMOGRANIN A; DISEASE PROGRESSION; HUMANS; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77950363326     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.068957     Document Type: Article

References (14)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
2. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion. 1993;54(suppl):72-75.
3. Janson ET, Oberg K. Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32:225-229. (Pubitemid 23188540)
4. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276-3281.
5. O'Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastroenteropancreatic endocrine tumours. Neuroendocrinology. 2004;80(suppl):79-84.
6. Plöckinger U, Wiedenmann B. Treatment of gastroenteropancreatic neuroendocrine tumours. Virchows Arch. 2007;451(suppl):S71-S80.
7. 177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
8. 177Lu-DOTA0,Tyr3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol. 2005;23:2754-2762.
9. 111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
10. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253. (Pubitemid 23008970)
11. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51:877-884. (Pubitemid 44030808)
12. Papotti M, Croce S, Macri L, et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol. 2000;9:47-57. (Pubitemid 30131962)
13. 90Y-DOTATOC. J Nucl Med. 2005;46:1310-1316.
14. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311-4318.